Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monacolin k + bifidobacterium longum bb536
- Development stage
- Unknown
- Lead developer
- Montefarmaco
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a **combination nutraceutical** composed of **monacolin K** (the principal hypocholesterolemic constituent of red yeast rice; structurally identical to lovastatin, an HMG-CoA reductase inhibitor) and the probiotic **Bifidobacterium longum BB536**. Monacolin K inhibits HMG-CoA reductase, reducing endogenous cholesterol synthesis, while Bifidobacterium longum BB536 (with high biliary salt hydrolase activity) may reduce cholesterol absorption in the intestine. In clinical studies of adults with moderate hypercholesterolemia and low cardiovascular risk, this combination has been shown to reduce total and LDL cholesterol, non-HDL cholesterol, and apolipoprotein B, without significant adverse events over 12 weeks. It is delivered as a powder and frequently marketed under the name "Lactoflorene Colesterolo". Primary indication is lipid lowering for cardiovascular risk reduction in subjects with moderate hypercholesterolemia[1][2][4].
- Brand names
- Lactoflorene Colesterolo
- Other names
- red yeast rice extract + bifidobacterium longum bb536
02
Targets
BSH (Bile salt hydrolase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on monacolin k + bifidobacterium longum bb536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monacolin k + bifidobacterium longum bb536.